Dose Recommendations for Drugs in Patients With Liver Cirrhosis (The ALIVe Study): Protocol for a Multiphase Validation and Consensus Study
Katharina Karsten Dafonte, Philipp Lutz, Christian Jansen, Christian P Strassburg, Robert Németh, Gunther Hartmann, Ulrich Jaehde, Martin Coenen, Javad Sarvestan · 2026
Read Dose Recommendations for Drugs in Patients With Liver Cirrhosis (The ALIVe Study): Protocol for a Multiphase Validation and Consensus Study by Katharina Karsten Dafonte, Philipp Lutz, Christian Jansen, Christian P Strassburg, Robert Németh, Gunther Hartmann, Ulrich Jaehde, Martin Coenen, Javad Sarvestan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13249594.txt.
Description
Karsten Dafonte and a German team lay out the ALIVe study, a 2026 protocol for dosing drugs safely in liver cirrhosis. A scarred liver clears many medicines slowly, yet no guideline tells doctors how to adjust doses for it. The project moves in three phases: harvest published dose advice and grade it, settle disagreements through expert Delphi rounds, then test the agreed advice in real patients.
The clinical phase began in January 2025, and one hundred twenty-one patients had enrolled by May 2026. Final results are expected in August 2026. The authors say combining literature, expert consensus, and bedside validation should yield dosing guidance sturdy enough for everyday practice.
Catalog record
| CREATOR | Katharina Karsten Dafonte, Philipp Lutz, Christian Jansen, Christian P Strassburg, Robert Németh, Gunther Hartmann, Ulrich Jaehde, Martin Coenen, Javad Sarvestan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |